Cerus’ (CERS) Hold Rating Reaffirmed at BTIG Research

BTIG Research reiterated their hold rating on shares of Cerus (NASDAQ:CERS) in a report published on Wednesday.

A number of other research firms have also commented on CERS. Zacks Investment Research lowered shares of Cerus from a hold rating to a sell rating in a research note on Tuesday, January 30th. BidaskClub upgraded shares of Cerus from a buy rating to a strong-buy rating in a research note on Thursday, March 15th. Cantor Fitzgerald reiterated a buy rating and set a $5.00 price objective on shares of Cerus in a research note on Tuesday, January 23rd. Finally, ValuEngine upgraded shares of Cerus from a hold rating to a buy rating in a research note on Friday, May 4th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $5.35.

Shares of NASDAQ:CERS opened at $6.58 on Wednesday. Cerus has a 52 week low of $1.93 and a 52 week high of $6.75. The company has a market capitalization of $821.13 million, a price-to-earnings ratio of -11.75 and a beta of 1.72. The company has a current ratio of 5.66, a quick ratio of 3.26 and a debt-to-equity ratio of 0.33.

Cerus (NASDAQ:CERS) last announced its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01. Cerus had a negative net margin of 111.46% and a negative return on equity of 111.19%. The company had revenue of $13.56 million for the quarter, compared to analyst estimates of $12.22 million. During the same quarter last year, the business earned ($0.18) earnings per share. Cerus’s revenue was up 93.4% compared to the same quarter last year. sell-side analysts predict that Cerus will post -0.45 EPS for the current year.

In related news, CEO William Mariner Greenman sold 7,735 shares of the firm’s stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $4.80, for a total transaction of $37,128.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Laurence M. Corash acquired 150,011 shares of the stock in a transaction that occurred on Thursday, March 15th. The shares were bought at an average price of $5.15 per share, for a total transaction of $772,556.65. Following the purchase, the insider now directly owns 1,462,580 shares of the company’s stock, valued at $7,532,287. The disclosure for this purchase can be found here. Insiders have sold 14,381 shares of company stock worth $69,685 in the last quarter. Company insiders own 7.40% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Rhumbline Advisers boosted its holdings in Cerus by 10.9% during the first quarter. Rhumbline Advisers now owns 107,397 shares of the biotechnology company’s stock worth $589,000 after buying an additional 10,580 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Cerus by 2.8% during the fourth quarter. Bank of New York Mellon Corp now owns 470,437 shares of the biotechnology company’s stock worth $1,590,000 after buying an additional 12,944 shares in the last quarter. California State Teachers Retirement System boosted its holdings in Cerus by 9.2% during the fourth quarter. California State Teachers Retirement System now owns 178,503 shares of the biotechnology company’s stock worth $603,000 after buying an additional 15,005 shares in the last quarter. Baird Financial Group Inc. boosted its holdings in Cerus by 17.6% during the fourth quarter. Baird Financial Group Inc. now owns 120,512 shares of the biotechnology company’s stock worth $407,000 after buying an additional 18,000 shares in the last quarter. Finally, Jump Trading LLC bought a new stake in Cerus during the first quarter worth approximately $104,000. Hedge funds and other institutional investors own 51.03% of the company’s stock.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Solaris Price Up 3.8% Over Last 7 Days
Solaris Price Up 3.8% Over Last 7 Days
EtherDelta Token 1-Day Volume Tops $1,922.00
EtherDelta Token 1-Day Volume Tops $1,922.00
Merit Medical Systems, Inc.  Receives $49.73 Average Target Price from Analysts
Merit Medical Systems, Inc. Receives $49.73 Average Target Price from Analysts
FirstCoin  Reaches 24-Hour Trading Volume of $3,088.00
FirstCoin Reaches 24-Hour Trading Volume of $3,088.00
Qube Price Up 5% Over Last Week
Qube Price Up 5% Over Last Week
Stipend  Tops 24 Hour Volume of $137,736.00
Stipend Tops 24 Hour Volume of $137,736.00


Leave a Reply

© 2006-2018 Ticker Report. Google+.